{"created":"2023-05-15T16:30:29.109908+00:00","id":1630,"links":{},"metadata":{"_buckets":{"deposit":"b59be887-757b-44b5-b4b0-59d604135155"},"_deposit":{"created_by":2,"id":"1630","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"1630"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00001630","sets":["10:11"]},"author_link":["7890","7894","7895","7891","7892","7893","7898","7897","7896"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-02-15","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"527","bibliographicPageStart":"521","bibliographicVolumeNumber":"58","bibliographic_titles":[{"bibliographic_title":"Internal Medicine"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Objective The standard anti-tuberculosis (TB) regimen occasionally causes acute kidney injury (AKI). The major etiology is rifampicin-induced acute interstitial nephritis. However, the standard management \nof AKI induced by anti-TB drugs has yet to be established. Methods We retrospectively reviewed patients with TB who developed AKI after starting standard anti-TB treatment between 2006 and 2016 at a single TB center. \nThe clinical characteristics and the management are described. Results Among 1,430 patients with active TB, 15 (1.01%) developed AKI. The mean age (standard devia-tion) was 61 years (18). The median (interquartile range) time to AKI development was 45 days (21-54 days). The median serum creatinine level before anti-TB treatment was 0.7 mg/dL (0.5-1.4 mg/dL), whereas the median peak serum creatinine level after AKI onset was 4.0 mg/dL (3.08-5.12 mg/dL). Five patients (33.3%) were pathologically confirmed as having acute interstitial nephritis (AIN), and 7 patients (46.7%) had a clinical diagnosis of the disease. All anti-TB drugs were stopped, \nand steroids were administered to 5 (100%) patients with pathologically confirmed AIN and 3 (42.8%) patients with clinically diagnosed AIN. The renal function was normalized in 12 patients (80.0%) after restarting anti-TB treatment without rifampicin (n=12) or isoniazid (n=1). \nTwo patients died due to severe renal failure after restarting rifampicin. \nConclusion Rifampicin is the leading cause of AKI. Levofloxacin may be an alternative to rifampicin thanks to its safety and potency. Restarting anti-TB treatment without rifampicin and short-term steroid administration may be a feasible management for AKI.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Internal Medicine, 58(4), pp.521-527; 2019　","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"日本内科学会"}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.2169/internalmedicine.0813-18","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"c 2019 The Japanese Society of Internal Medicine. The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/)."}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"09182918","subitem_source_identifier_type":"ISSN"}]},"item_2_source_id_8":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"13497235","subitem_source_identifier_type":"ISSN"}]},"item_2_text_62":{"attribute_name":"出版者別言語","attribute_value_mlt":[{"subitem_text_value":"Japanese Society of Internal Medicine"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Sakashita, Kentaro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Murata, Kengo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Takahashi, Yukiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yamamoto, Miake"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Oohashi, Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sato, Yu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kitazono, Miyako"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Wada, Akihiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Takamori, Mikio"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-18"}],"displaytype":"detail","filename":"IntMed58_521.pdf","filesize":[{"value":"303.4 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"IntMed58_521.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/1630/files/IntMed58_521.pdf"},"version_id":"58cc5939-b04b-40ce-bc97-82d340eacc25"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Acute interstitial nephritis","subitem_subject_scheme":"Other"},{"subitem_subject":"Acute kidney injury","subitem_subject_scheme":"Other"},{"subitem_subject":"Rifampicin","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"A Case Series of Acute Kidney Injury During Anti-tuberculosis Treatment","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"A Case Series of Acute Kidney Injury During Anti-tuberculosis Treatment"}]},"item_type_id":"2","owner":"2","path":["11"],"pubdate":{"attribute_name":"公開日","attribute_value":"2019-03-26"},"publish_date":"2019-03-26","publish_status":"0","recid":"1630","relation_version_is_last":true,"title":["A Case Series of Acute Kidney Injury During Anti-tuberculosis Treatment"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-16T03:59:02.433299+00:00"}